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1. Introduction
Lung cancer is a widely seen disease making up 13% of 
all cancers, being responsible for 18% (1.4 million) of 
cancer-related deaths (1). It is the major cause of cancer-
related mortalities in both sexes across the world. The 
most important reason for high mortality is the diagnosis 
being determined at a late stage in 70% of cases, when no 
effective treatment is available (2,3). Moreover, resection 
in patients who present with an advanced stage of lung 
cancer is not appropriate and such patients can only benefit 
from chemotherapy. The primary pathological diagnosis 
in advanced stage patients, who represent the majority 
of the cases, is established through a limited number of 
specimens from small biopsies and cytology samples (2). 
The four major types of lung cancer are small 
cell carcinoma (SCC) and nonsmall cell carcinomas 
(NSCLC) including squamous cell carcinoma (SqCC), 
adenocarcinoma (AC), and large cell carcinoma (LCC). 
Until recently, it was sufficient to distinguish SqCC from 
NSCLC, as management was similar for all subtypes of 
NSCLC (4,5). With the development of new biological 
agents, accurate distinction between AC and SqCC is 
now critical as histological subtyping is important in 
clinical decision making (6). In particular, if the tumor 
represents a less differentiated or heterogeneous area in 
small biopsy and cytological samples, the contribution of 
available immunohistochemical markers to a differential 
diagnosis becomes even more limited. There is now a 
greater obligation on pathologists to accurately subtype 
NSCLC in small biopsy specimens with the help of 
immunohistochemical and molecular markers (7).
Napsin-A is an aspartic proteinase enclosed in 
the cytoplasm of type II pneumocytes and alveolar 
macrophages in the lungs and plays a role in the maturation 
of surfactant protein-B. Besides the lungs, it is also found 
in the kidneys’ proximal tubule and convoluted tubule 
epithelia (8). It regulates the absorption and catabolism 
of the proteins in the proximal tubules of the kidneys (9). 
Background/aim: The aim of this study was to investigate Napsin-A, NTRK-1, NTRK-2, Desmoglein-3, and Desmocollin-3 in the 
differential diagnosis and prognosis of nonsmall cell lung cancer.
Materials and methods: The expression of Napsin-A, NTRK-1, NTRK-2, and Desmoglein-3 was examined by immunohistochemistry 
in 50 squamous cell carcinomas and 50 adenocarcinomas. Desmocollin-3 was investigated in 29 squamous cell carcinoma and 29 
adenocarcinoma cases. Associations between expression profiles of Napsin-A, NTRK-1, NTRK-2, Desmoglein-3, and Desmocollin-3 in 
lung cancers and clinicopathological variables were analyzed. 
Results: Napsin-A staining was statistically significant in detecting adenocarcinomas versus squamous cell carcinomas. The sensitivity of 
Napsin-A for adenocarcinomas was 96% and the specificity was 100%. NTRK-2 and Desmocollin-3 staining were statistically significant 
in detecting squamous cell carcinomas versus adenocarcinomas. Desmoglein-3, Napsin-A, and NTRK-2 had no effect on survival. 
Disease-free survival time was significantly shorter in cases that were moderately positive with NTRK-1.
Conclusion: Our data suggest that Napsin-A, NTRK-2, and Desmocollin-3 are useful markers in the differentiation of nonsmall cell 
lung cancer.
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It is a specific marker for pulmonary adenocarcinomas 
and for a small portion of papillary-type renal cell and 
papillary-type thyroid carcinomas. It is thought to be a 
very useful marker when used in combination with TTF-1 
in distinguishing between primary adenocarcinomas and 
metastatic adenocarcinomas of the lungs (8). 
The neurotrophic tyrosine kinase receptors NTRK-1 
and NTRK-2 are from the family of neuron growth factor 
receptors responsible for neuronal development. They play 
a major role in neuronal proliferation and cell survival. 
Activation of the NTRK gene in the alveolar cells of the 
lungs regulates the survival and proliferation of alveolar 
cells. On the other hand, inhibition of NTRK induces 
apoptosis and reduces clonogenicity. Strong expressions 
of NTRK-1 have been reported in normal epidermis, oral 
mucosa, and epidermal carcinomas (basal cell carcinoma 
and squamous cell carcinoma). NTRK-2 is found in 
normal lung, liver, and heart tissues. Unlike NTRK-1, it 
has not been detected in normal epidermis, normal oral 
mucosa, basal cell carcinoma, or squamous cell carcinomas 
of the skin. NTRK-1 and NTRK-2 have been found to 
be expressed more strongely in immunohistochemical 
terms in squamous differentiation than in glandular 
differentiation. It has been reported that they can be useful 
in distinguishing SqCC from AC, especially in small 
samples such as needle biopsies that cannot be diagnosed 
in histological terms (6,10). 
Desmoglein-3 is an adhesion protein of the cadherin 
family that is expressed in the stratified squamous 
epithelium (3). Desmocollin-3 shows stronger expression 
in the basal layers of the stratified squamous epithelium 
and is localized in the desmosomal junction of epithelial 
cells. It shows weaker expression in the basal layers of 
columnar epithelia of trachea and bronchi in the lungs 
(11). Desmocollin-3 and Desmoglein-3 are suggested to be 
valuable new immunohistochemical markers in squamous 
differentiation (3,11). 
The aim of the present study was to determine the 
role of TTF-1, p63, Napsin-A, NTRK-1, NTRK-2, and 
Desmoglein-3 and Desmocollin-3 in the diagnosis of 
SqCC and AC of the lung and to investigate the possible 
use of these markers in the differential diagnosis and 
prognosis of SqCC and subtypes of AC. The sensitivity and 
the specificity values of each marker were compared.  
2. Materials and methods
We retrospectively investigated 100 cases of pulmonary 
carcinoma, 50 being SqCC and 50 AC, which had been 
diagnosed at the Pathology Department of Pamukkale 
University Faculty of Medicine between 2007 and 2013. 
The cancer stages ranged between I and IV and no 
chemotherapy was administered to the patients but 58% 
underwent lobectomy, 28% pneumonectomy, and 14% 
wedge resection. Records from the electronic hospital 
data were searched for demographic information, the 
tumor’s preoperative phase, types of treatment, durations 
of follow-up, and disease outcomes (disease-free survival, 
overall survival, relapse, and cancer-related mortality 
data). The diagnosis of pulmonary carcinoma in the 
histological sections of the resection materials of each 
patient, the tumor’s differentiation, and the presence of 
metastatic lymph node dissection materials were reviewed 
and assessed.
In the histopathological examinations, the SqCC 
patients were assessed based on the 2004 classification of 
the WHO. The AC cases were reclassified in view of the 
guidelines published by IASLC/ATS/ERS collectively in 
2011 (12), which are recommended for resection specimens. 
Tumor staging was carried out according to the criteria in 
the American Joint Committee for Cancer Staging and End 
Results Reporting (AJCSS) for 2009 (13,14). 
A specimen reflecting the tumor tissue best was chosen 
from each case. Five pieces of 3-µm sections were taken 
for each case from the chosen paraffin blocks and placed 
on positive loaded slides to work on Napsin-A, NTRK-1, 
NTRK-2, Desmoglein-3, and Desmocollin-3 antibodies. 
Then, with the help of a VENTANA BenchMark LT device, 
they were stained automatically using anti-Napsin-A 
antibody (clone EPR6252, Abcam, 1/250 dilution), 
NTRK-1 antibody (clone 0193R, Bioss, 1/100 dilution), 
NTRK-2 antibody (clone 0175R, Bioss, 1/100 dilution), 
anti-Desmoglein-3 antibody (clone 6585R, Bioss, 1/100 
dilution), anti-Desmocollin-3 antibody (clone EPR7486, 
Abcam, 1/50 dilution), p63 (clone 7 JUL, Novocastra, 
dilution 1/25), and TTF-1 (clone SP141, Novocastra, 
ready-to-use). 
Cases were assessed assuming that granular 
cytoplasmic staining displays positivity for Napsin-A. The 
positive controls of Napsin-A were type II pneumocytes 
and alveolar macrophages. Cytoplasmic staining with or 
without circumferential membranous involvement was 
considered positive for NTRK-1 and NTRK-2. Sporadic 
nuclear positivity was also assessed. The skin was used 
as the positive control of NTRK-1 and the alveolar 
macrophages were used as the positive control for NTRK-
2. Skin tissue was used as positive control for Desmoglein-3 
and Desmocollin-3. Cytoplasmic and nuclear staining 
with Desmoglein-3 in varying amounts was considered as 
positive. Cytoplasmic staining and marked membranous 
staining were considered as positive for Desmocollin-3. 
The semiquantitative and subjective grading system 
was used for Napsin-A, NTRK-1, NTRK-2, Desmoglein-3, 
and Desmocollin-3 to examine the intensity of staining 
and the staining rate of tumor cells in 4 categories: 0: no 
staining, 1: mild staining, 2: moderate staining, 3: marked 
staining.
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The statistical analyses were carried out using SPSS 
17.0 for Windows. The Kruskall–Wallis H test was used 
to compare the variables between the SqCC and AC 
groups, logistic multivariate regression analysis was used 
to compare the immunohistochemical staining between 
the two groups, and the Kaplan–Meier test was used for 
the analysis of survival.
3. Results
The clinical follow-up information was obtained for all 
the subjects included in the study. The clinicopathologic 
data are summarized in Table 1. Histologically, 50 of 
the subjects (50%) showed SqCC and 50 of them (50%) 
AC morphology. From those who had AC, 16 (32%) had 
papillary, 13 (26%) acinar, 8 (16%) solid, 7 (14%) lepidic, 
5 (10%) micropapillary, and 1 (2%) minimal invasive 
subtypes of adenocarcinoma. From the SqCC cases, 16 
(32%) showed well differentiated, 21 (42%) moderately 
differentiated, and 13 (26%) poorly differentiated SqCC 
morphology. From the AC cases, 8 (16%) showed well 
differentiated, 29 (58%) moderately differentiated, and 13 
(26%) poorly differentiated AC morphology. The smallest 
tumor diameter was 1 cm and the largest 10 cm, with a 
mean diameter of 4.01 ± 2.09 cm. Angiolymphatic invasion 
was found in 49 of the tumors (49.0%). Tumors were found 
at the bronchial surgery border in 2 (2.3%) of the 84 patients 
who underwent lobectomy and pneumonectomy. One of 
these patients was in the SqCC group and the other in the 
AC group. Pleural involvement evaluation revealed that the 
tumor infiltrated the visceral pleura in 15 (15%) patients.
According to the new AJCSS lung cancer staging system 
for 2009, the distribution of the cases by their stages was 
as follows: in the SqCC group, 8 patients were at Stage IA 
(8%), 12 patients at Stage IB (12%), 8 patients at Stage IIA 
(8%), 12 patients at Stage IIB (12%), 4 patients at Stage IIIA 
(4%), and 6 patients at Stage IV (6%). In the AC group, 
15 patients were at Stage IA (15%), 4 patients at Stage IB 
(4%), 12 patients at Stage IIA (12%), 5 patients at Stage IIB 
(5%), 4 patients at Stage IIIA (4%), and 10 patients at Stage 
IV (10%). There was no statistically significant correlation 
between the distribution of cases by stages or tumor types 
(P > 0.05). 
Table 1. Characteristics and clinicopathologic findings of lung cancer cases.
SqCC Number of cases (n) AC Number of cases (n) Percent (%)
 Age
                40–65 33 32 65
                 >65 17 18 35
Sex
                 Male 50 39 89
                 Female 0 11 11
Localization
                 Right lung 28 31 59
                 Left lung 22 19 41
Metastasis status
                  Yes 6 10 16
                  No 44 40 84
Recurrence status
                  Yes 3 9 12
                  No 47 41 88
Survival status
                  Alive 30 34 64
                  Exitus 20 16 36
SqCC: squamous cell carcinoma, AC: adenocarcinoma 
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All patients in the SqCC group were male; 39 (78%) 
of the patients in the AC group were male and 11 (22%) 
were female. The difference between tumor type and sex 
was statistically significant (P = 0.01). No statistically 
significant difference was seen between tumor type and 
age groups, the localization of the tumor, bronchial surgery 
border, pleural involvement, angiolymphatic invasion, 
stage, relapse, distant organ metastasis, or exitus (P > 0.05). 
The most sensitive marker was p63 (100%) for SqCC 
in all SqCC cases, followed by Desmocollin-3 (96.6%), 
Desmoglein-3, and NTRK-2 (both 94%). The most specific 
marker for SqCCs was p63 (98%), and then came NTRK-2 
(36%) and Desmocollin-3 (34.5%). TTF-1 (100%) was the 
most sensitive marker for AC in all AC and SqCC cases; 
it was followed by Napsin-A (96%). The most specific 
marker for ACs was Napsin-A (100%) and then came 
TTF-1 (98%) (Table 2).
We found a statistically significant difference in favor 
of adenocarcinoma versus SqCC (P < 0.05) in the analysis 
of Napsin-A staining and tumor type. Excluding the solid 
type, all other AC subtypes showed marked staining with 
Napsin-A. Napsin-A staining in one of the AC cases is 
shown in Figure 1a. Napsin-A staining was also positive in 
tumor-free areas, type-II pneumocytes, foamy histiocytes, 
and some necrotic areas.
In all of the 100 cases, varying degrees of cytoplasmic 
staining with NTRK-1 were observed in many areas 
although nuclear staining was less frequent. No 
relationship between NTRK-1 staining and tumor type 
was observed (P > 0.05). Comparison of the degrees of 
staining revealed that 14 of SqCCs (28%) showed mild, 15 
(30%) moderate, and 21 (42%) marked staining, whereas 
6 of the adenocarcinomas (12%) displayed mild, 11 (22%) 
moderate, and 33 (66%) marked staining. Comparison of 
mildly stained materials with moderately and markedly 
stained cases exposed no statistically significant difference 
between these two groups in terms of the degree of staining 
with NTRK-1 (P > 0.05). 
Analysis of NTRK-2 staining and tumor type revealed 
a statistically significant difference in detecting SqCC (P < 
0.05). NTRK-2 staining in one of the SqCC cases is shown 
in Figure 1b. Analysis of Desmoglein-3 staining and tumor 
type showed no statistically significant difference (P > 0.05). 
Apparent staining in tumor giant cells was remarkable 
in addition to positive staining with Desmoglein-3 in 
nontumor pulmonary parenchyma, type II pneumocytes, 
inflammatory cells, secretions, endothelial cells, and 
chondrocytes. 
Analysis of Desmocollin-3 staining and tumor type 
showed a statistically significant difference in detecting 
SqCC (P < 0.05). Desmocollin-3 staining in one of the 
SqCC cases is shown in Figure 1c. With Desmocollin-3, 
positive staining was seen in some type-II pneumocytes, 
alveolar macrophages, bronchial epithelium, endothelial 
cells, and in seromucous gland cells in nontumor 
pulmonary parenchyma. 
Fifty patients in the SqCC group were followed up for 
between 2 and 74 months and 20 of them (40%) had died by 
the end of the follow-up period. The disease-free survival 
time was 46.8 ± 4.5 months for SqCC patients. Patients 
in the AC group were followed up for between 1 and 76 
months and 16 of them (32%) had died by the end of the 
Table 2. Tumor type and expression of markers in lung cancer cases.
SqCC n (%) AC n (%) P
TTF-1 (+)
TTF-1 (–)
1 (2)
49 (98)
50 (50)
0 (0) <0.05
p63 (+)
p63 (–)
50 (50)
0 (0)
1 (2)
49 (98) <0.05
Napsin-A (+)
Napsin-A (–)
0 (0)
50 (100)
48 (96)
2 (4) <0.05
NTRK-1 (+)
NTRK-1 (–)
36 (72)
14 (28)
44 (88)
 6 (12) >0.05
NTRK-2 (+)
NTRK-2 (–)
47 (94)
3 (6)
32 (64)
18 (36) <0.05
Desmoglein (+)
Desmoglein (–)
47 (94)
3 (6)
46 (92)
4 (8) >0.05
Desmocollin (+)
Desmocollin (–)
28 (96.6)
1 (3.4)
19 (65.5)
10 (34.5) <0.05
SqCC: squamous cell carcinoma, AC: adenocarcinoma
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follow-up period. The disease-free survival time was 50.1 
± 5.2 months for AC patients. The relationship between 
tumor type and disease-free survival was statistically 
insignificant (P > 0.05). 
Analysis of stage and tumor type revealed a mean 
survival time of 64.7 ± 3.8 months at stage I, 44.4 ± 5.1 
months at stage II, 13.11 ± 3.5 months at stage III, and 27.0 
± 4.3 months at stage IV. Being at stage I had a protective 
effect independent of other factors (odds ratio = stage I/
stage IV: 0.15 95% confidence interval: 0.04–0.52) and 
prolonged survival time. The relationship between tumor 
stage and disease-free survival was also statistically 
significant (P < 0.05). 
Analysis of immunohistochemical markers and 
survival time showed that the relationship between 
survival and Napsin-A (P > 0.05), NTRK-2 (P > 0.05), 
Desmoglein-3 (P > 0.05), and Desmocollin-3 (P > 0.05) 
was statistically insignificant. However, disease-free 
survival time was shorter in NTRK-1 moderately stained 
cases than in mild stained cases (P > 0.05) (odds ratio 
for NTRK-1 moderately positive = 3.7; 95% confidence 
interval: 1.3–10.6) (Figure 2). 
Apart from this, no significant relationship was found 
between survival and tumor type, tumor subtype, tumor 
diameter, patient age, sex, tumor localization, lymph node 
metastasis, or angiolymphatic invasion. 
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Figure 1a) Marked Napsin-A staining in one of the AC cases (Napsin-Ax100 ihc).  408 
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Figure 1 b) NTRK-2 staining in SqCC (NTRK-2 x100 ihc).  411 
412 
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Figure 1 c) Marked Desmoglein-3 positivity in SqCC (Desmoglein-3x100 ihc).  414 
415 
Figure 1a. Marked Napsin-A staining in one of the AC cases 
(Napsin-A × 100 ihc). 
Figure 1c. Marked Desmoglein-3 positivity in SqCC 
(Desmoglein-3 × 100 ihc). 
Figure 1b. NTRK-2 staining in SqCC (NTRK-2 × 100 ihc). 
a
b
c
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4. Discussion
We found that TTF-1 was the most sensitive marker 
and Napsin-A the most specific marker in pulmonary 
adenocarcinomas, while p63 showed the highest specificity 
and sensitivity in SqCC. With respect to sensitivity, p63 
was followed by Desmocollin-3 (96.6%) and Desmoglein-3 
(94%).
Many studies have shown that Napsin-A 
positivity ranges between 58% and 91% in pulmonary 
adenocarcinomas (8,15–19). In our study, Napsin-A was 
the marker with the highest specificity (100%) and the 
second highest sensitivity (96%) after TTF-1. As reported 
in many studies in the literature, we also found manifest 
Napsin-A negativity for SqCC (20–23). 
A study that investigated Napsin-A staining in 
bronchioloalveolar carcinomas reported that most of the 
cases were Napsin-A positive. In their series of mucinous 
and nonmucinous bronchioloalveolar carcinomas, 
Napsin-A was more sensitive than TTF-1 (20). In our 
study, 8 of the 50 AC cases were lepidic predominant 
type (nonmucinous bronchioloalveolar carcinoma as per 
2004 WHO) and all of them showed marked staining with 
Napsin-A as was the case in the above study. Napsin-A 
was reported to show significantly higher positivity 
than surfactant protein A in acinar, papillary, and mixed 
subtypes of adenocarcinomas (19). We also found higher 
degrees of staining with Napsin-A in the acinar and 
papillary subtypes, in concordance with this result. 
In another study investigating 686 primary pulmonary 
cancers, NTRK-1 showed high specificity (92.8%) but 
relatively low sensitivity (71.6%) in SqCC (10). In the same 
study, NTRK-2 was also found to be specific (96.4%) for 
SqCC but with quite low sensitivity (51.3%). The sensitivity 
of NTRK-1 for SqCC was 72% and the specificity was 28% 
in our study. Our study presents comparable results with 
a sensitivity of 94% and a specificity of 6% for NTRK-2 
in SqCC cases. Our findings suggest that NTRK-2 can 
be a useful marker in showing squamous differentiation. 
Zhang et al. studied 60 patients with nonsmall cell 
lung cancer with NTRK-2 and reported that NTRK-2 
expression was positive in 40 (66.7%) of the patients. A 
statistically significant correlation was found in these cases 
only between the NTRK-2 expression and the TNM stage 
and lymph node metastasis (24). In our study, 94% of the 
SqCC cases and 64% of the AC cases were found NTRK-
2 positive and, in contrast with this study, we observed a 
significant difference in favor of SqCC between the NTRK-
2 expression and the tumor’s histological type. 
In a study by Tsuta et al., Desmocollin-3 was found 
to be the most sensitive marker (with 100% specificity) 
in SqCC (25). We found the specificity of Desmocollin-3 
to be quite lower (3.4%) in SqCC, but its sensitivity was 
higher (96.6%). 
Another study revealed Desmocollin-3 positivity in 
nearly a half of the 62 undifferentiated LCC cases and 
TTF-1 negativity in all of these cases (11). The authors 
concluded that Desmocollin-3 was expressed in a portion 
of pulmonary LCC and that these cases were not stained 
with TTF-1. They stated that an immunohistochemical 
panel including Desmocollin-3 and TTF-1 would assist 
in determining morphology in such cases. In accordance 
with this, we also found that Desmocollin-3 is a useful 
marker in determining squamous differentiation and we 
also suggest that Desmocollin-3 should be present in the 
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Figure 2. Relation between NTRK-1 staining and disease-free survival rate. 
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panel when dealing with undifferentiated tumors whose 
differential diagnoses cannot be established in small 
biopsy and cytology materials. 
Fukuoka et al. showed that Desmoglein-3 had 88% 
specificity and 98% sensitivity for SqCC compared 
with AC. They also found that Desmoglein-3 positivity 
was associated with a poor prognosis (26). Cui et al. 
reported that Desmocollin-3 was a potential diagnostic 
marker for SqCC in primary pulmonary tumors and that 
Desmocollin-3 DNA hypermethylation was correlated 
with poor prognosis and the Desmocollin-3 gene acted 
like a new tumor suppressor gene that inhibits EGFR (27). 
We could not report any significant effect on prognosis 
with Desmoglein-3.
A study exploring the effect of Napsin-A on prognosis 
in pulmonary AC reported that Napsin-A negativity 
was an independent prognostic factor reducing patient 
survival (28). In our study, 47 of the pulmonary AC cases 
were Napsin-A positive. Only 3 cases were not stained 
with Napsin-A and since the number of patients was small 
in this group, the prognostic significance of Napsin-A 
in AC was not studied statistically. When the entire 100 
cases were assessed, Napsin-A was found not to have a 
significant effect on survival. 
A study suggested that NTRK-1 staining does not have 
a significant effect on the prognosis of SqCC and AC but 
is a positive prognostic factor for SqCC in patient survival 
irrespective of sex, stage, age, and smoking (10). They 
observed improvements in the disease-related survivals 
of NTRK-2 positive SqCC cases but the effect of NTRK-
2 on survival in AC cases was statistically insignificant 
(10). Contrasting this, we found that disease-free survival 
time was significantly shorter in moderately NTRK-1 
positive stained cases compared with mildly positive cases, 
irrespective of the histological subtype and independent of 
other variables. However, we observed that NTRK-2 did 
not have any significant effect on the prognosis of SqCC 
and we did not see any significant relationship between 
NTRK-2 and TNM or lymph node metastasis. 
In conclusion, we showed that Napsin-A, NTRK-2, 
and Desmocollin-3 staining have statistically significant 
meaning in detecting squamous cell carcinomas versus 
adenocarcinomas. Desmoglein-3, Napsin-A, and NTRK-2 
had no effect on prognosis but disease-free survival time 
was significantly shorter in cases that were moderately 
positively stained with NTRK-1. 
We think that including Napsin-A, NTRK-2, and 
Desmocollin-3 in the panel together with p63, TTF-1, 
and mucin will improve differential diagnosis in cases of 
“NSCC, not otherwise specified” that cannot be diagnosed 
with available stains. However, larger studies are needed to 
test this observation.
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